United Services Automobile Association Has $326,000 Stock Holdings in Organon & Co. (NYSE:OGN)

United Services Automobile Association lowered its position in shares of Organon & Co. (NYSE:OGN) by 16.4% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 17,063 shares of the company’s stock after selling 3,339 shares during the quarter. United Services Automobile Association’s holdings in Organon & Co. were worth $326,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of OGN. Cetera Advisors LLC acquired a new position in shares of Organon & Co. during the 1st quarter worth about $322,000. CWM LLC grew its stake in Organon & Co. by 39.9% in the second quarter. CWM LLC now owns 32,470 shares of the company’s stock valued at $672,000 after purchasing an additional 9,259 shares in the last quarter. Simplicity Wealth LLC acquired a new position in shares of Organon & Co. during the 2nd quarter worth approximately $249,000. SG Americas Securities LLC bought a new stake in shares of Organon & Co. during the 2nd quarter worth approximately $180,000. Finally, Wedmont Private Capital raised its stake in shares of Organon & Co. by 66.7% during the 2nd quarter. Wedmont Private Capital now owns 19,382 shares of the company’s stock worth $413,000 after purchasing an additional 7,754 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Wall Street Analyst Weigh In

OGN has been the subject of several analyst reports. JPMorgan Chase & Co. cut shares of Organon & Co. from a “neutral” rating to an “underweight” rating and raised their target price for the company from $18.00 to $20.00 in a research note on Friday, September 6th. Evercore ISI upgraded shares of Organon & Co. to a “strong-buy” rating in a research note on Wednesday, September 18th.

Organon & Co. Stock Performance

Shares of NYSE OGN opened at $15.05 on Tuesday. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The company has a market capitalization of $3.87 billion, a P/E ratio of 2.99, a P/E/G ratio of 0.71 and a beta of 0.75. Organon & Co. has a 12 month low of $10.97 and a 12 month high of $23.10. The stock has a 50 day moving average of $16.71 and a 200-day moving average of $19.33.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.03). The company had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.56 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. Organon & Co.’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.78 earnings per share. As a group, equities research analysts predict that Organon & Co. will post 3.89 EPS for the current year.

Organon & Co. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Tuesday, November 12th will be given a dividend of $0.28 per share. The ex-dividend date of this dividend is Tuesday, November 12th. This represents a $1.12 annualized dividend and a yield of 7.44%. Organon & Co.’s dividend payout ratio (DPR) is presently 22.22%.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.